Guest Editors
Dr. Paulina Gil-Kulik
Email: pgil.poczt@vp.pl
Affiliation: Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland
Homepage:
Research Interests: cancer, cancer epigenetics, non-coding RNA, stem cells, mesenchymal stem cells, gene expression, microRNA, breast mik
Dr. Alicja Petniak
Email: alicja.petniak@umlub.pl
Affiliation: Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland
Homepage:
Research Interests: microRNA, cancer, stem cells, mesenchymal stem cells, gene expression
Summary
The classical genetic model of cancer has evolved into a complex landscape where epigenetic alterations play a decisive role in tumorigenesis and clinical outcomes. This Special Issue explores the intricate interplay between the epigenetic machinery—including DNA methylation, histone modifications, and chromatin remodeling—and the vast network of non-coding RNAs (miRNAs, lncRNAs, and circRNAs). We focus on how these epigenetic drivers orchestrate tumor progression and, crucially, how they mediate resistance to conventional and targeted therapies. By bridging the gap between basic molecular research and clinical application, this issue aims to highlight innovative epigenetic-targeted approaches, including "epidrugs" and ncRNA-based delivery systems. We invite original research and comprehensive reviews that shed light on the diagnostic, prognostic, and therapeutic potential of the cancer epigenome.
Keywords
cancer epigenetics, non-coding RNA (ncRNA), therapy resistance, epigenetic targeted therapy
Login
Register
Submit a Paper
Propose a Special lssue